KR102690198B1 - 신경근육, 신경퇴행, 자가면역, 발달 및/또는 대사 질환의 치료를 위한 뇌 유도된 신경친화성 인자(bdnf)의 유도된 발현 - Google Patents

신경근육, 신경퇴행, 자가면역, 발달 및/또는 대사 질환의 치료를 위한 뇌 유도된 신경친화성 인자(bdnf)의 유도된 발현 Download PDF

Info

Publication number
KR102690198B1
KR102690198B1 KR1020177023034A KR20177023034A KR102690198B1 KR 102690198 B1 KR102690198 B1 KR 102690198B1 KR 1020177023034 A KR1020177023034 A KR 1020177023034A KR 20177023034 A KR20177023034 A KR 20177023034A KR 102690198 B1 KR102690198 B1 KR 102690198B1
Authority
KR
South Korea
Prior art keywords
disease
effective dose
prevent
treat
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177023034A
Other languages
English (en)
Korean (ko)
Other versions
KR20170104597A (ko
Inventor
로버트 알론소
존 제라드 가이슬러
Original Assignee
미토콘 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미토콘 파마슈티칼스, 인크. filed Critical 미토콘 파마슈티칼스, 인크.
Publication of KR20170104597A publication Critical patent/KR20170104597A/ko
Application granted granted Critical
Publication of KR102690198B1 publication Critical patent/KR102690198B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020177023034A 2015-01-22 2016-01-21 신경근육, 신경퇴행, 자가면역, 발달 및/또는 대사 질환의 치료를 위한 뇌 유도된 신경친화성 인자(bdnf)의 유도된 발현 Active KR102690198B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562106365P 2015-01-22 2015-01-22
US62/106,365 2015-01-22
PCT/US2016/014312 WO2016118741A1 (en) 2015-01-22 2016-01-21 Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

Publications (2)

Publication Number Publication Date
KR20170104597A KR20170104597A (ko) 2017-09-15
KR102690198B1 true KR102690198B1 (ko) 2024-07-30

Family

ID=55310938

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177023034A Active KR102690198B1 (ko) 2015-01-22 2016-01-21 신경근육, 신경퇴행, 자가면역, 발달 및/또는 대사 질환의 치료를 위한 뇌 유도된 신경친화성 인자(bdnf)의 유도된 발현

Country Status (13)

Country Link
US (6) US9763896B2 (https=)
EP (2) EP4306167B1 (https=)
JP (3) JP6951976B2 (https=)
KR (1) KR102690198B1 (https=)
CN (2) CN107405315A (https=)
AU (2) AU2016209255B2 (https=)
BR (1) BR112017015721A2 (https=)
CA (1) CA2974092A1 (https=)
ES (2) ES2961334T3 (https=)
HK (1) HK1247101A1 (https=)
MX (2) MX392410B (https=)
PT (1) PT3247340T (https=)
WO (1) WO2016118741A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107405315A (zh) 2015-01-22 2017-11-28 米托充制药公司 用于治疗神经肌肉、神经变性、自身免疫、发育和/或代谢疾病的脑源性神经营养因子(bdnf)的诱导表达
WO2018129258A1 (en) 2017-01-06 2018-07-12 Gencia Corporation Novel phenyl derivatives
AU2018215056A1 (en) * 2017-01-31 2019-08-08 Charles E. Inturrisi D-methadone and its derivatives for use in the treatment of disorders of the nervous system
CA3061201A1 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP4223307A4 (en) * 2020-09-29 2024-07-24 Cefo Co., Ltd. COMPOSITION FOR THE PREVENTION OR TREATMENT OF A NEUROPSYCHOLOGICAL DISEASE, COMPRISING MANF
WO2023205625A2 (en) * 2022-04-18 2023-10-26 Mitochon Pharmaceuticals, Inc. 2,4 dnp and prodrugs thereof for treatment of pulmonary and autoimmune diseases
WO2025051360A1 (en) * 2023-09-06 2025-03-13 Instituto de Medicina Molecular João Lobo Antunes Trkb-t1 agonist for the treatment of absence seizure and/or comorbidities

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664297B1 (en) * 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1764095A1 (en) * 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
US20100130597A1 (en) 2007-07-06 2010-05-27 The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service Dna-pkcs modulates energy regulation and brain function
WO2015031756A1 (en) * 2013-08-30 2015-03-05 Yale University Novel 2,4-dinitrophenol formulations and methods using same
CN107405315A (zh) * 2015-01-22 2017-11-28 米托充制药公司 用于治疗神经肌肉、神经变性、自身免疫、发育和/或代谢疾病的脑源性神经营养因子(bdnf)的诱导表达

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Acta Pharmacologica Sinica 34: 765-776 (2013) 1부.*
IUBMB Life, Vol.58, No.4,p.185-191 (2006) 1부.*

Also Published As

Publication number Publication date
US20190142765A1 (en) 2019-05-16
US9974755B2 (en) 2018-05-22
BR112017015721A2 (pt) 2018-04-10
CA2974092A1 (en) 2016-07-28
JP2021080286A (ja) 2021-05-27
US20170065536A1 (en) 2017-03-09
WO2016118741A1 (en) 2016-07-28
JP2018502898A (ja) 2018-02-01
EP4306167A2 (en) 2024-01-17
ES3057870T3 (en) 2026-03-05
AU2021240120A1 (en) 2021-10-28
US11717497B2 (en) 2023-08-08
HK1247101A1 (zh) 2018-09-21
US9763896B2 (en) 2017-09-19
EP3247340B1 (en) 2023-08-02
EP3247340A1 (en) 2017-11-29
MX2017009402A (es) 2017-12-04
PT3247340T (pt) 2023-10-31
KR20170104597A (ko) 2017-09-15
AU2016209255A1 (en) 2017-08-10
JP2022173519A (ja) 2022-11-18
EP4306167C0 (en) 2025-12-24
EP4306167A3 (en) 2024-03-20
CN116617195A (zh) 2023-08-22
MX392410B (es) 2025-03-11
US20240156750A1 (en) 2024-05-16
US20210052513A1 (en) 2021-02-25
CN107405315A (zh) 2017-11-28
US10220006B2 (en) 2019-03-05
US20160213625A1 (en) 2016-07-28
EP4306167B1 (en) 2025-12-24
JP7440092B2 (ja) 2024-02-28
ES2961334T3 (es) 2024-03-11
US10864173B2 (en) 2020-12-15
US20180125794A1 (en) 2018-05-10
AU2016209255B2 (en) 2021-07-01
MX2022005937A (es) 2022-06-29
JP6951976B2 (ja) 2021-10-20

Similar Documents

Publication Publication Date Title
KR102690198B1 (ko) 신경근육, 신경퇴행, 자가면역, 발달 및/또는 대사 질환의 치료를 위한 뇌 유도된 신경친화성 인자(bdnf)의 유도된 발현
Hanaya et al. The new antiepileptic drugs: their neuropharmacology and clinical indications
US20250188461A1 (en) Methods of treating osmidrosis
WO2020198039A1 (en) Ketamine for treatment of sensory processing deficits
ES2922284T3 (es) Uso de una dieta que simula el ayuno para mejorar la eficacia de los antiestrógenos en terapia contra el cáncer
KR20220109378A (ko) 병용 요법 방법, 조성물 및 키트
HK40106997A (en) Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
Sharma et al. Recovery of the injured neural system through gene delivery to surviving neurons in Parkinson’s disease
RU2858090C2 (ru) Применение боратных производных в лечении нейродегенеративных заболеваний
JP2021530567A (ja) 安息香酸塩または安息香酸誘導体を含む、抗ｎ−メチル−ｄ−アスパラギン酸受容体脳炎を予防または治療するための医薬組成物
CA3076180C (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
EP2991645B1 (en) Biotin for use in treating x-linked adrenoleukodystrophy
Reichmann et al. NEW DEVELOPMENTS FOR PARKINSON’S THERAPY WITH COMT INHIBITORS
Zafardoost et al. Evaluation of the Effect of Glibenclamide on the Short Time Prognosis of Patients With Diffuse Axonal Injury Due to Moderate to Severe Head Trauma
Kafantaris et al. Post-Acute Effectiveness of Lithium in Pediatric Bipolar I Disorder
Tankosic Parkinson's disease: new dopaminergic delivery but neuroprotection remains elusive

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601